
|Articles|April 6, 2023
Live Broadcast: Explore the Efficacy and Safety Data for a Treatment Option for Certain Patients With ESR1-Mutated ER+/HER2- mBC
Advertisement
In an upcoming broadcast, Medical Doctors Hope Rugo and Joyce O'Shaughnessy will discuss important clinical efficacy and safety data for a new treatment option for certain patients with ESR1-mutated, ER+/HER2- mBC following disease progression.
To obtain expert perspective and learn about the efficacy and safety data of this new treatment option, watch the live broadcast on April 25, 2023 and May 1, 2023. To register for the event, visit
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5






























